Williams to Report First-Quarter 2025 Financial Results on May 5; Earnings Conference Call and Webcast Scheduled for May 6
TULSA, Okla.–(BUSINESS WIRE)–Williams (NYSE: WMB) plans to announce its first-quarter 2025 financial results after the market closes on Monday, May 5,... Read more.
Vince Holding Corp. Names Yuji Okumura Chief Financial Officer
The Company Plans to Report Fourth Quarter and Fiscal Year 2024 Financial Results on May 2, 2025 NEW YORK–(BUSINESS WIRE)–Vince Holding Corp., (NYSE:... Read more.
NEUPATH APPOINTS STEPHEN LEMIEUX AS PRESIDENT TO DRIVE NEXT PHASE OF STRATEGIC GROWTH
New role strengthens executive team’s ability to leverage operational turnaround, improved cash flow and recently secured credit facility to accelerate growth... Read more.
Harvest ETFs Announces TSX Listing of New Low Vol ETFs
OAKVILLE, Ontario–(BUSINESS WIRE)–Harvest Portfolios Group Inc. (“Harvest”, “Harvest ETFs”) is pleased to announce the completion of the initial... Read more.
Albertsons Companies, Inc. Reports Fourth Quarter and Full Year Results
BOISE, Idaho–(BUSINESS WIRE)–Albertsons Companies, Inc. (NYSE: ACI) (the “Company”) today reported results for the fourth quarter of fiscal... Read more.
BizCap® Arranges $175MM to Accelerate Growth for Oil & Gas Infrastructure and Utility Services Leader
SAN FRANCISCO–(BUSINESS WIRE)–#commercial—BizCap®, a national commercial finance and advisory firm, today announced that it has successfully facilitated... Read more.
Pulsate Enhances Data Processing Capabilities, Driving Targeted Campaign Success
DUBLIN–(BUSINESS WIRE)–Pulsate, provider of mobile-first engagement solutions that deepen digital banking relationships and cut through noise in consumers’... Read more.
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS®... Read more.
Promega HiBiT-PsVLP Bioassay to Aid Global Vaccine Research
Promega HiBiT-PsVLP Bioassay enables simple, safe study without infectious viral particles. Assay supports collaboration between Charles River and CEPI’s Centralised... Read more.
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
– Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression... Read more.